HIV/AIDS News and Research

RSS

Acquired immune deficiency syndrome or acquired immunodeficiency syndrome (AIDS) is a disease of the human immune system caused by the human immunodeficiency virus (HIV).

ACTG announces the launch of clinical trial to evaluate new CMV vaccine in adults

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the launch of A5355, a clinical trial studying a new cytomegalovirus (CMV) vaccine in adults with both HIV and CMV.

16 Dec 2021

Hotel-based protective housing minimizes COVID-19 rates in vulnerable homeless population

Persons experiencing homelessness (PEH) who were at high risk of severe COVID-19 were 2.5 times less likely to contract SARS-CoV-2 if they were provided with individual hotel rooms and medical and social support compared to citywide rates in homeless shelters, according to new research from the University of Chicago Medicine, Lawndale Christian Health Center, and the Chicago Department of Public Health.

13 Dec 2021

New insights about COVID-19 vaccination rates among people living with HIV

The AIDS Clinical Trials Group, the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that insights around COVID-19 vaccination rates among people living with HV have been published in the Journal of Infectious Diseases.

10 Dec 2021

'Combination' adjuvant may boost the protective power of vaccines

Scientists at La Jolla Institute for Immunology and Massachusetts Institute of Technology, have found a possible way to improve the effectiveness of COVID-19 vaccines-;and any vaccine.

4 Dec 2021

New nanoparticle adjuvant could help make vaccines more powerful

A common strategy to make vaccines more powerful is to deliver them along with an adjuvant -; a compound that stimulates the immune system to produce a stronger response.

3 Dec 2021

WHO recommends the use of first long-acting option to protect women from HIV

The first long-acting option to protect women from HIV, proven to reduce women's HIV risk, has been recommended for use by the World Health Organization.

1 Dec 2021

Substantial efforts needed to help people with HIV achieve durable viral suppression, study suggests

Among people with HIV worldwide who are receiving antiretroviral therapy (ART), adults are getting closer to the global target of 95% achieving viral suppression, but progress among children and adolescents is lagging and long-term viral suppression among all groups remains a challenge.

30 Nov 2021

Study suggests substantial efforts are needed to help people with HIV durably suppress the virus

30 Nov 2021

COVID-19 infections in the fully vaccinated are rare but are common in people with weak immune systems

A real-world retrospective cohort study involving nearly 1.2 million people shows COVID-19 infections in the 'fully' vaccinated are rare but are more common and severe in people with weaker immune systems.

30 Nov 2021

Comprehensive genomic study maps the global resurgence of syphilis

The most comprehensive genomic study of syphilis to date has mapped the recent resurgence of the disease around the world.

26 Nov 2021

Researchers map how far HIV patients live from access to care

In sub-Saharan Africa, 7 million people with HIV live more than 10 minutes from health care services and 1.5 million people with HIV live more than 60 minutes from a healthcare facility, according to a new study published this week in the open-access journal PLOS Global Public Health by Diego Cuadros of the University of Cincinnati, and colleagues.

25 Nov 2021

Red blood cell distribution width as a biomarker for COVID-19

A review highlights the prospects and challenges of RDW as a predictive biomarker for viral infections, with a special focus on COVID-19 and hepatitis.

22 Nov 2021

Novel technique solves structure of the HIV capsid alone and in complex with host factors

A new technique using electron tomography and subtomogram averaging at Diamond's electron Bio-Imaging Centre (eBIC), has solved the structure of the HIV capsid alone and in complex with host factors.

21 Nov 2021

Antiretroviral drugs detected in drinking water

Years ago, there was a time that kids from a rural village in South Africa still wanted to swim in the rivers nearby. But when they got out of the water, those with sensitive skins would have the worst rash ever, says Prof Philiswa Nomngongo.

18 Nov 2021

Study tracks risk and protective behaviors related to transmission of HIV/AIDS in young adults

A number of behaviors in younger adults that increase risk for the transmission of HIV/AIDS have declined or changed between 2010 and 2020, according to the national Monitoring the Future study.

10 Nov 2021

ACTG announces launch of clinical trial evaluating a three-month TB treatment

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the launch of A5362 (CLO-FAST), a clinical trial studying a three-month clofazimine- and high-dose rifapentine-containing treatment regimen for people with drug-susceptible tuberculosis (TB).

10 Nov 2021

Investigational inhaled COVID-19 treatment graduates to phase 3 in ACTIV-2 trial

The AIDS Clinical Trials Group, the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that the external data and safety monitoring board (DSMB) has recommended that SNG001, an inhaled formulation of interferon beta, advance to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).

21 Oct 2021

Novel trial uses a virtual village to treat HIV-associated loneliness

A new clinical trial designed by Maile Young Karris, MD, internal medicine physician and infectious disease specialist at UC San Diego Health, seeks to discover whether people living with HIV can benefit from emotional support offered by a virtual community, and from physical support and services delivered by community volunteers.

21 Oct 2021

COVID-19 vaccine breakthrough infections among immunocompromised individuals

A study of breakthrough infections in immunocompromised people following two doses of the Pfizer/BioNTech vaccine against SARS-CoV-2 concluded that immunocompromised people would be best served with a third dose of the vaccine for better protection.

19 Oct 2021

ACTG to present data highlighting a new therapeutic for COVID-19 at the virtual IDWeek 2021

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that Teresa H. Evering, M.D., M.S., a co-lead investigator (with Eric S. Daar, M.D.) for BRII-196/BRII-198 in the ACTIV-2 study of Outpatient Monoclonal Antibodies and Other Therapies, will present data for the monoclonal antibody combination at the virtual IDWeek 2021 conference, taking place September 29 – October 3, 2021.

30 Sep 2021

HIV/AIDS News and Research

Further Reading

ACTG announces the launch of clinical trial to evaluate new CMV vaccine in adults

Hotel-based protective housing minimizes COVID-19 rates in vulnerable homeless population

New insights about COVID-19 vaccination rates among people living with HIV

'Combination' adjuvant may boost the protective power of vaccines

New nanoparticle adjuvant could help make vaccines more powerful

WHO recommends the use of first long-acting option to protect women from HIV

Substantial efforts needed to help people with HIV achieve durable viral suppression, study suggests

Study suggests substantial efforts are needed to help people with HIV durably suppress the virus

COVID-19 infections in the fully vaccinated are rare but are common in people with weak immune systems

Comprehensive genomic study maps the global resurgence of syphilis

Researchers map how far HIV patients live from access to care

Red blood cell distribution width as a biomarker for COVID-19

Novel technique solves structure of the HIV capsid alone and in complex with host factors

Antiretroviral drugs detected in drinking water

Study tracks risk and protective behaviors related to transmission of HIV/AIDS in young adults

ACTG announces launch of clinical trial evaluating a three-month TB treatment

Investigational inhaled COVID-19 treatment graduates to phase 3 in ACTIV-2 trial

Novel trial uses a virtual village to treat HIV-associated loneliness

COVID-19 vaccine breakthrough infections among immunocompromised individuals

ACTG to present data highlighting a new therapeutic for COVID-19 at the virtual IDWeek 2021

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News